{"name":"Minerva Neurosciences","slug":"minerva-neurosciences","ticker":"NERV","exchange":"NASDAQ","domain":"minervaneurosciences.com","description":"","hq":"Waltham, MA","founded":0,"employees":"","ceo":"","sector":"CNS / Psychiatry","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":41175600,"revenueGrowth":0,"grossMargin":0,"rdSpend":5759473,"netIncome":-293423177,"cash":82301813,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MIN-117 5.0 mg","genericName":"MIN-117 5.0 mg","slug":"min-117-5-0-mg","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"MIN-117 5.0 mg","genericName":"MIN-117 5.0 mg","slug":"min-117-5-0-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9iS2R5RS13cjV6NjNRWG10dXRzS2hvMmQwSDNGVVE4Ujd5MVc1eEhRdm00NHBmUzZWNWw1QlRVZDN1WU1ZbFF3T2RRRURNQWZQLWREZ09pVElYTUFOV3JhdzNLazNTYWRJUjZqZ2drc2R5VkFO?oc=5","date":"2026-04-02","type":"pipeline","source":"Investing News Network","summary":"Minerva Announces Leadership Transition - Investing News Network","headline":"Minerva Announces Leadership Transition","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOTmxwcUlfdnJyV2ZFVVdldUZoOW1ZX2tqRGNYdFdYWVV0LXg4ekc1Q0QyOHhCRnFRNXNUNVBuUk1wSG1jbVI3aVdEXzZObHA0QmJOM2l6ZGpYQ3VxRFpsUEE3amI4TmZmTEs5cmh5N0IxYmFHcmMtOHZCRnBjUk9ORWxPdXk2M25vR182OHJNTmZkbDlGSk9EWkt1ejVaRV9GSldqV3l1YThhUUp0eE1kRlRMc3gtLTJYd0NQUkJMdUZjT1ZhYnVVQU1McHFrSEk0T3BjNTBVbm9RS3VpT0YtR3had04xb1VkeGxXeVU5WTIxQ0V3V0tNZVZnVDEzRjFjZXI4TDJsUlNNaXdNOE54S0NkRl9kM2N0MEE?oc=5","date":"2026-03-31","type":"trial","source":"Investing News Network","summary":"Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - Investing News Network","headline":"Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Trea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNZVBvMUtMVEp0S0piNUxId0F4Qjl1TTctc3MwelExUXdPSkNqbTlmRWV2bVMwakJZWnVVVmhveDdFeFp4elY0S2ZmdXh2d2NYSlZBd3doQnJsR1lveXVwR3hnM3FmeFRKTVB4SjRkYjViYkZfdWlWSEU5OEpsQ2RqdDNaUlFNdlFxUWdhc0JIU0s2Z1BDQUwyRzZPb1hhZG44TXdvVEN1WHVJdFZIUXdRUFZJRWJlNHFqRnlVaGJLR3lEYVlsOTR2S0lCQWdERzBUaVVENFAxSUtqQjlIaEFQRjlTSmdISEpXUEZObUFwUnB5bjhuWnhJ?oc=5","date":"2026-03-25","type":"regulatory","source":"Investing News Network","summary":"Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - Investing News Network","headline":"Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanza","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5jeEI2TjJTbVNuY180TUQ5N2hGeGQ1Y1IwZjM5bmt4N01tOXJuN1BnMGc5Zm5mMk1BeXYycnQ5VVJ2dk5yZ3VhUlBpXzZKVVBTcVFVVWU4aTFBQUhYcW13dEg5OGU4VGk0NENMX2FR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Minerva Neurosci (NERV) - Stock Titan","headline":"If You Invested $1,000 in Minerva Neurosci (NERV)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQa1hfX045b2FGbjVSV2NDZVB4OGwta2paaVdvdU5IemhiVmNhTml5V0R3ZEYzcGdpX2hxUC1nS0owZ2RVN3FlY3Znek5hbHdTeTJ6RHg3TS1kNmFnNFlIQU50WW8tVWs5bVVqR0twQVhBeXJxVnRRRndZNDkwam9ld0ktMmRnUUpCaVRqVWVRWklUREp2RndWZ1lTOV9aczg0eVE?oc=5","date":"2026-03-12","type":"pipeline","source":"Investing News Network","summary":"Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network","headline":"Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum","sentiment":"neutral"},{"date":"2026-03-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-16","type":"pipeline","source":"simplywall.st","summary":"Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st","headline":"Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who o","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOT1RqcnNBZ2dHMVp1Vk9JNVVhNTFGRl9CU3M5VVhFT2pXS2ZYMk8yZkFONTVEMWk4Qzg4c2s3elV0TFBWYTVaQnR0QkxCSWlRdVZqcTU1bGRwU0NYN2huMi1rbjNsNTh3NlJlZF9INjNGSGlyMk0ySThsUWxQZDhvYVB6VjE?oc=5","date":"2025-10-21","type":"pipeline","source":"StocksToTrade","summary":"Minerva Neurosciences’ Unexpected Surge: Should You Invest? - StocksToTrade","headline":"Minerva Neurosciences’ Unexpected Surge: Should You Invest?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1FekJUa2RSTjU4cXp4TmQ1OTIzRVZKRERHcnpLZGlINl83VkkzSzBmUWdudWtfRTZQOENROURnOHhsZTNTM1BLQ3pvTlVrcDM0T0t2OFF3eXdzMEhWNi1kclpuVjNlUVZuUWNlcVEyN0REX1kwX0x3TVhDN19Sdw?oc=5","date":"2025-10-21","type":"deal","source":"Rolling Out","summary":"Minerva Neurosciences stock skyrockets after $200M deal - Rolling Out","headline":"Minerva Neurosciences stock skyrockets after $200M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPV0VrVm9YNDVkX3ZIX0ZfWGd0eDBNQ2Nxc2J5MDk4VEl4alJKTzdBUXcxM040aXBOSnFhZnpycDkzcHRTeThLLVJsVjU5enFYdExTSnRWMF85ZjZBT1ZIR1dTQkRYd3huSTAtVlZxTGxQWFRPWWM5YkhfRmJMUWxYTk5fZVF5QlJrUk9rZjJvTWdjdmk2N0hlSkl4RkUzX3ZJeDlYSThoa191eXhURHk0aldGNGNTcUpmYVdFMA?oc=5","date":"2025-10-21","type":"trial","source":"Stock Titan","summary":"Minerva Neurosciences (NASDAQ: NERV) secures up to $200M for roluperidone Phase 3 - Stock Titan","headline":"Minerva Neurosciences (NASDAQ: NERV) secures up to $200M for roluperidone Phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPR2JfMlo2LUthMFFESW0zOE5LWERZUTZqNmpJd2prcm9rV0FYVEliWjVXY1ZLUXhZTTg5RmF0SmxWbXVhSTgtbTRFY2VQLThsS3ltZ3pyenl0T3pJaGhma1ZoWGRFaUVYZDRnYjNqTzhyWnlKWDExY0puM2JMemdOdmUzdDBaVzlzQ1B0ZDhVNTVBcEJsM2JEYktSR2EwbVZVSVdTMExIdFF2QzlkSlRVX0gtRE9MNFdBT1diNWhKd3A3blpUOHpISnFWYldjckE5T2NQcXlDSkNIc2NjNlhnWm9Kd0ZVck4tanZQZVNPRXFJZDU0a3VHN1gzVlVnLVc4Q1YzRzVNb3g?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire","headline":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":41175600,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":41175600,"period":"2020-12-31"},{"value":0,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5759473,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-293423177,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":82301813,"cashHistory":[],"totalAssets":97968888,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}